GFAP and glioblastoma: Muller et al. identified CTCs in PB from 29 of 141 (20.6%) GBM patients by immunostaining of enriched mononuclear cells with antibodies directed against GFAP and stated that CTCs are “intrinsic property” of GBM biology [10].